A prospective interventional study to evaluate a strategy of point-of-care testing for sexually transmitted infections including chlamydia, gonorrhoea, trichomoniasis, syphilis, and Hepatitis B with comprehensive case management including partner notification in antenatal settings in Harare province, Zimbabwe.
Sexually transmitted infections (STIs) can cause serious morbidity including pelvic inflammatory disease, infertility, poor mental health, adverse pregnancy outcomes and an increased risk of HIV transmission. In low and middle-income countries (LMICs), STIs are treated using syndromic management, which has poor sensitivity and specificity, leading to considerable levels of both underdiagnosis and overtreatment. In recent years, simpler diagnostic platforms for STIs have been developed. Development and evaluation of strategies for provision of diagnostic testing in LMICs are needed and the World Health Organization (WHO) has called for evidence to inform replacement of syndromic management by diagnostic testing. The aim of this project is to evaluate a strategy of point-of-care (POC) testing for STIs including chlamydia, gonorrhoea, trichomoniasis, syphilis, and Hepatitis B with comprehensive case management including partner notification in antenatal settings in Harare province, Zimbabwe. The objectives are to: 1. Determine the uptake, prevalence and yield of chlamydia, gonorrhoea, trichomoniasis, syphilis and hepatitis B testing, and risk factors for infection among women attending for antenatal care 2. Assess the acceptability and feasibility of this intervention 3. Estimate the cost and cost-effectiveness of POC STI testing 4. Investigate the prevalence of antimicrobial resistance for Neisseria gonorrhoeae to inform the development of a gonococcal antimicrobial resistance surveillance programme 5. Assess an incentives-based approach to optimize uptake of client-referral partner notification. A prospective interventional study will be conducted in three primary healthcare clinics (PHCs) in Harare province, Zimbabwe. 1000 pregnant women will be recruited over a nine month period when registering for routine antenatal care. Testing will be staggered across sites so that testing will be available at each site for three months within the nine-month study period. All Identified STIs will be managed comprehensively including treatment and/or referral if required according to national guidelines, and partner notification and risk reduction counselling. Given the relatively low number of gonococcal isolates likely to be obtained from pregnant women alone, men attending the PHCs with urethral discharge will be recruited to gain sufficient numbers to establish a surveillance programme. Urethral samples will be collected from 140 men with urethral discharge, to support the assessment of antimicrobial resistance amongst patients with gonorrhoea.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Enrollment
1,005
Testing for: * Chlamydia and gonorrhoea using the GeneXpert platform (Cepheid) * Trichomoniasis using the OSOM Trichomonas Rapid Test (Sekisui Diagnostics) * HIV and syphilis using the SD BIOLINE HIV/Syphilis Duo (Abbott Diagnostics Medical Co. Ltd) * Hepatitis B using the HBsAg2 rapid test (Abbott Diagnostics Medical Co. Ltd)
Mbare polyclinic
Harare, Zimbabwe
Composite STI prevalence
Composite % of participants with chlamydia, gonorrhoea, trichomoniasis, syphilis, and/or hepatitis B
Time frame: Through study completion, up to 1 year
Individual STI prevalences
Individual % of participants with chlamydia, gonorrhoea, trichomoniasis, syphilis, and hepatitis B
Time frame: Through study completion, up to 1 year
Uptake of STI testing
% of individuals approached who accept and undergo testing
Time frame: Through study completion, up to 1 year
Yield of STI testing
% of individuals approached who test positive for an STI
Time frame: Through study completion, up to 1 year
Uptake of treatment
% of participants with a curable STI who accept treatment
Time frame: Through study completion, up to 1 year
Uptake of partner notification
% of participants with a curable STI who undertake partner notification
Time frame: Through study completion, up to 1 year
Prevalence of antimicrobial resistance in gonococcal isolates
% of gonococcal isolates with resistance to ceftriaxone, cefixime, azithromycin, and ciprofloxacin
Time frame: Through study completion, up to 1 year
Prevalence of adverse birth outcomes
% of pregnancies with premature birth, miscarriage, or low birth weight
Time frame: Through study completion, up to 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.